Skip to main content


Fig. 1 | Journal of Translational Medicine

Fig. 1

From: A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer

Fig. 1

Diagram of treatment. Prior to the start of the trial patients will have an implantable port that access the peritoneum placed surgically. Patients will have their monocytes isolated by counter-flow elutriation and stimulated with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) ex vivo. The monocytes and interferons will be infused IP by gravity in 250 mL Plasmalyte A, followed by a 250 mL saline wash. The patient will rotate from the supine position to left prostrate, followed by left prostrate, every 15 min for 2 h to ensure movement of the product within the peritoneum

Back to article page